All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Andrew DaviesDuring the European School of Haematology (ESH)'s 2nd How to Diagnose & Treat Lymphoma conference, the Lymphoma Hub spoke to Andrew Davies, University of Southampton, Southampton, UK. We asked, When will we be seeing changes in the frontline treatment of diffuse large B-cell lymphoma (DLBCL)?
When will we be seeing changes in the frontline treatment of DLBCL?
Andrew Davies starts by describing the changes in treatment selection that has already started to occur for patients with standard risk disease. He then discusses the situation for patients with high-risk DLBCL, which is yet to undergo such a shift. The different approaches that have been tested are listed, but it is acknowledged that R-CHOP protocols remain the standard of care for this group. The impact of molecular profiling and patient stratification are examined.